XML 51 R7.htm IDEA: XBRL DOCUMENT v2.4.1.9
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
12 Months Ended
Dec. 31, 2014
Dec. 31, 2013
Dec. 31, 2012
Cash Flows From Operating Activities:      
Net loss $ (95,708)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (62,124)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic $ (39,444)us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic
Adjustments to reconcile net loss to net cash used in operating activities:      
Depreciation and amortization 120us-gaap_DepreciationDepletionAndAmortization 56us-gaap_DepreciationDepletionAndAmortization 2us-gaap_DepreciationDepletionAndAmortization
Amortization of deferred financing costs 411us-gaap_AmortizationOfFinancingCosts    
Loss on disposal of property and equipment     2us-gaap_GainLossOnSaleOfPropertyPlantEquipment
Stock-based compensation expense 4,722us-gaap_ShareBasedCompensation 4,614us-gaap_ShareBasedCompensation 2,515us-gaap_ShareBasedCompensation
Accretion of discount/premium on available for sale securities 130us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments 59us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments (86)us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments
Change in fair value of derivative instruments-warrants (1,362)us-gaap_UnrealizedGainLossOnDerivatives (149)us-gaap_UnrealizedGainLossOnDerivatives 1,933us-gaap_UnrealizedGainLossOnDerivatives
Changes in operating assets and liabilities:      
Security deposit (69)us-gaap_IncreaseDecreaseInSecurityDeposits   (5)us-gaap_IncreaseDecreaseInSecurityDeposits
Accounts payable and accrued expenses 316us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 7,084us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities 4,442us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
Prepaid expenses and other current assets (124)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (2,171)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets (484)us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
Accrued interest expense on Senior Convertible Debentures 2,500us-gaap_IncreaseDecreaseInInterestPayableNet    
Total Adjustments 6,644us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities 9,493us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities 8,319us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities
Net Cash used in Operating Activities (89,064)us-gaap_NetCashProvidedByUsedInOperatingActivities (52,631)us-gaap_NetCashProvidedByUsedInOperatingActivities (31,125)us-gaap_NetCashProvidedByUsedInOperatingActivities
Cash Flows From Investing Activities:      
Loans to related parties   (270)us-gaap_PaymentsToFundLongtermLoansToRelatedParties (1,764)us-gaap_PaymentsToFundLongtermLoansToRelatedParties
Net purchases of available-for-sale securities   (30,000)us-gaap_PaymentsToAcquireAvailableForSaleSecurities (20,000)us-gaap_PaymentsToAcquireAvailableForSaleSecurities
Additions to property and equipment (173)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (615)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment (28)us-gaap_PaymentsToAcquirePropertyPlantAndEquipment
Repayment on ContraVir loan receivable 455us-gaap_ProceedsFromCollectionOfNotesReceivable    
Net Cash provided by /(used in) Investing Activities 282us-gaap_NetCashProvidedByUsedInInvestingActivities (30,885)us-gaap_NetCashProvidedByUsedInInvestingActivities (21,792)us-gaap_NetCashProvidedByUsedInInvestingActivities
Cash Flows From Financing Activities:      
Proceeds of sale of common stock 30,700us-gaap_ProceedsFromIssuanceOfCommonStock 94,734us-gaap_ProceedsFromIssuanceOfCommonStock 55,862us-gaap_ProceedsFromIssuanceOfCommonStock
Proceeds of sale of common stock - ContraVir 3,224us-gaap_ProceedsFromIssuanceOfPrivatePlacement    
Issuance of Senior Convertible Debentures 200,000us-gaap_ProceedsFromConvertibleDebt    
Payment for debt financing costs (12,747)us-gaap_PaymentsOfFinancingCosts    
Fees and expenses related to sale of common stock (861)us-gaap_PaymentsOfStockIssuanceCosts (5,623)us-gaap_PaymentsOfStockIssuanceCosts (3,774)us-gaap_PaymentsOfStockIssuanceCosts
Proceeds from exercise of stock options 36us-gaap_ProceedsFromStockOptionsExercised 119us-gaap_ProceedsFromStockOptionsExercised  
Distribution associated with ContraVir Spinoff (3,230)sgyp_DistributionSpinoffTransaction    
Net Cash provided by Financing Activities 217,122us-gaap_NetCashProvidedByUsedInFinancingActivities 89,230us-gaap_NetCashProvidedByUsedInFinancingActivities 52,088us-gaap_NetCashProvidedByUsedInFinancingActivities
Net increase/(decrease) in cash and cash equivalents 128,340us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease 5,714us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease (829)us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease
Cash and cash equivalents at beginning of period 18,130us-gaap_CashAndCashEquivalentsAtCarryingValue 12,416us-gaap_CashAndCashEquivalentsAtCarryingValue 13,245us-gaap_CashAndCashEquivalentsAtCarryingValue
Cash and cash equivalents at end of period 146,470us-gaap_CashAndCashEquivalentsAtCarryingValue 18,130us-gaap_CashAndCashEquivalentsAtCarryingValue 12,416us-gaap_CashAndCashEquivalentsAtCarryingValue
Supplementary disclosure of cash flow information:      
Cash paid for taxes 55us-gaap_IncomeTaxesPaid 81us-gaap_IncomeTaxesPaid 50us-gaap_IncomeTaxesPaid
Supplementary disclosure of non-cash investing and financing activities:      
Distribution of net assets of ContraVir $ 84sgyp_NonCashInvestingAndFinancingActivitiesDistributionOfNetAssets